TrialTransplantation and cellular therapy2023

A Multicenter Phase 2 Clinical Trial of 10-Day Decitabine, Dose-Escalated Donor Lymphocyte Infusion, and Ruxolitinib for Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Cell Transplantation.

Armin Rashidi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.